Metabolomics approach reveals key plasma biomarkers in multiple myeloma for diagnosis, staging, and prognosis
Abstract Background Multiple myeloma (MM) is the most aggressive and prevalent primary malignant tumor within the blood system, and can be classified into grades RISS-I, II, and III. High-grade tumors are associated with decreased survival rates and increased recurrence rates. To better understand m...
Saved in:
Main Authors: | Xiaoxue Wang, Longhao Cheng, Aijun Liu, Lihong Liu, Lili Gong, Guolin Shen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-02-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-024-05848-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia
by: Camille Tessier, et al.
Published: (2024-09-01) -
Synchronous multiple myeloma and lung adenocarcinoma: A clinical series
by: Fang Ye, et al.
Published: (2024-04-01) -
Large-scale prospective serum metabolomic profiling reveals candidate predictive biomarkers for suspected preeclampsia patients
by: Yan Cao, et al.
Published: (2025-02-01) -
A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients
by: Wang M, et al.
Published: (2025-02-01) -
Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01)